Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

1/2 (Der p 1/Der p 2) are regarded as important allergens of house dust mite (HDM). However, the effect of both products on the epithelial barrier and immune response of patients with and without HDM allergic rhinitis (AR) remains unclear. Air-liquid interface (ALI) cultured human nasal epithelial cells (HNECs) derived from control subjects (non-AR) ( = 9) and HDM-AR patients ( = 9) were treated with Der P 1 and Der P 2, followed by testing the transepithelial electrical resistance (TEER), paracellular permeability of fluorescein isothiocyanate (FITC)-dextrans and immunofluorescence of claudin-1 and ZO-1. Interleukin-6 (IL-6) production was evaluated by ELISA. Der p 1 reduced TEER significantly in a transient and dose-dependent manner in HNEC-ALI cultures from HDM-AR and non-AR patients, whilst the paracellular permeability was not affected. TEER was significantly reduced by Der p 1 at the 10-min time point in HDM-AR patients compared to non-AR patients ( = 0.0259). Compared to no-treatment control, in HNECs derived from HDM-AR patients, Der p 1 significantly cleaved claudin-1 after 30 min exposure (72.7 ± 9.5 % in non-AR group, 39.9 ± 7.1 % in HDM-AR group, = 0.0286) and induced IL-6 secretion ( = 0.0271). Our results suggest that patients with HDM-AR are more sensitive to Der p 1 than non-AR patients with increased effects of Der p1 on the mucosal barrier and induction of inflammation, indicating an important role for Der p1 in sensitization and HDM-AR development.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974687PMC
http://dx.doi.org/10.3389/falgy.2021.692049DOI Listing

Publication Analysis

Top Keywords

hdm-ar patients
12
non-ar patients
12
der
10
patients
9
epithelial barrier
8
il-6 production
8
house dust
8
dust mite
8
allergic rhinitis
8
hnecs derived
8

Similar Publications

Real-world surveillance of standardized quality (SQ) house dust mite sublingual immunotherapy tablets for 3 years in Japan.

Allergy Asthma Proc

January 2025

Department of Pharmacovigilance, Pharmacovigilance and Quality Assurance Group, Torii Pharmaceutical Co., Ltd., Tokyo, Japan.

Standardized quality (SQ) house-dust mite (HDM) sublingual immunotherapy tablets (10,000 Japanese allergy units [JAU], equivalent to 6 SQ-HDM in Europe and the United States) are licensed for the treatment of HDM-induced allergic rhinitis (AR) without age restriction, based on 52-week administration clinical trials. There are no large-scale data on the administration of 10,000 JAU for > 1 year in actual clinical practice. To examine the safety and effectiveness of 10,000 JAU during use for up to 3 years at real-world clinical sites in Japan.

View Article and Find Full Text PDF

Background: Establishing the interaction between aeroallergens and air pollution in children with house dust mite induced allergic rhinitis (HDM-AR) remains challenging, especially in urban areas. The coronavirus disease 2019 (COVID-19) pandemic and the subsequent lockdown measures provided a valuable opportunity.

Methods: We analyzed the clinical data of HDM-AR children between March and August in 2018-2020, and classified the children according to the type and the degree of HDM sensitization.

View Article and Find Full Text PDF
Article Synopsis
  • The 300IR house dust mite (HDM) sublingual immunotherapy (SLIT) tablet is approved for treating allergic rhinitis caused by dust mites, and a comprehensive review was conducted on its safety based on clinical trial and post-marketing data.
  • In randomized controlled trials (RCTs), 1,853 subjects received the 300IR HDM-SLIT tablet, showing mainly mild to moderate adverse events, particularly at the beginning of treatment, with no reported cases of anaphylaxis.
  • Over 7 years of real-world data corroborated the favorable safety profile of the 300IR HDM-SLIT tablet across various age groups and asthma statuses, with rare severe reactions noted.
View Article and Find Full Text PDF

Background: House dust mite (HDM)-induced allergic rhinitis (AR) is a major cause of allergic respiratory disease. The efficacy and safety of the 300 IR HDM sublingual immunotherapy (SLIT) tablet in patients with moderate-to-severe HDM-AR was confirmed in a large, international, phase 3 randomized controlled trials (RCTs). Here, we analyzed the results in the European population.

View Article and Find Full Text PDF

Clinical characteristics of local allergic rhinitis sensitized to house dust mites in Asia.

Eur Arch Otorhinolaryngol

May 2024

Department of Otorhinolaryngology-Head and Neck Surgery, Guro Hospital, Korea University College of Medicine, 148 Gurodong-Ro, Guro-Gu, Seoul, 08308, Republic of Korea.

Purpose: Local allergic rhinitis (LAR) is characterized by a localized nasal allergic response without evidence of systemic atopy. LAR is an underdiagnosed entity and is a diagnostic and therapeutic challenge for clinicians. This study aimed to investigate the prevalence and clinical characteristics of patients with LAR to house dust mites (LAR-HDM) in Korea.

View Article and Find Full Text PDF